SDZ logo

Sandoz Group AGWBAG:SDZ Stock Report

Market Cap €29.5b
Share Price
€68.32
€72.47
5.7% undervalued intrinsic discount
1Yn/a
7D-0.7%
Portfolio Value
​
View

Sandoz Group AG

WBAG:SDZ Stock Report

Market Cap: €29.5b

Sandoz Group (SDZ) Stock Overview

Develops, manufactures, and markets generic and biosimilars worldwide. More details

SDZ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance2/6
Financial Health6/6
Dividends2/6

Rewards

Trading at 34.3% below our estimate of its fair value

Earnings are forecast to grow 16.75% per year

Risk Analysis

No risks detected for SDZ from our risk checks.

SDZ Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.3% undervalued intrinsic discount
5022.2%Revenue growth p.a.
3.7k
23
2
55
1mo ago

Sandoz Group AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sandoz Group
Historical stock prices
Current Share PriceCHF 68.32
52 Week HighCHF 78.84
52 Week LowCHF 52.52
Beta0.61
1 Month Change-0.35%
3 Month Change3.48%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO28.32%

Recent News & Updates

Recent updates

Shareholder Returns

SDZAT PharmaceuticalsAT Market
7D-0.7%-0.3%0.1%
1Yn/a6.7%29.4%

Return vs Industry: Insufficient data to determine how SDZ performed against the Austrian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how SDZ performed against the Austrian Market.

Price Volatility

Is SDZ's price volatile compared to industry and market?
SDZ volatility
SDZ Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement5.0%
10% most volatile stocks in AT Market7.1%
10% least volatile stocks in AT Market2.5%

Stable Share Price: SDZ has not had significant price volatility in the past 3 months compared to the Austrian market.

Volatility Over Time: SDZ's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
188622,356Richard Saynorwww.sandoz.com

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms.

Sandoz Group AG Fundamentals Summary

How do Sandoz Group's earnings and revenue compare to its market cap?
SDZ fundamental statistics
Market cap€29.54b
Earnings (TTM)€779.92m
Revenue (TTM)€9.52b
37.9x
P/E Ratio
3.1x
P/S Ratio

Is SDZ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SDZ income statement (TTM)
RevenueUS$11.16b
Cost of RevenueUS$5.86b
Gross ProfitUS$5.30b
Other ExpensesUS$4.39b
EarningsUS$914.00m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

Aug 05, 2026

Earnings per share (EPS)2.11
Gross Margin47.50%
Net Profit Margin8.19%
Debt/Equity Ratio56.6%

How did SDZ perform over the long term?

See historical performance and comparison

Dividends

1.3%
Current Dividend Yield
48%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/03 19:34
End of Day Share Price 2026/04/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sandoz Group AG is covered by 37 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily FieldBarclays
James GordonBarclays
Sidhartha ModiBarclays